Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis.
Journal: Transplantation and cellular therapy
Published: August 12, 2025
Patient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan.
Journal: Frontiers in oncology
Published: March 07, 2025
The prognostic value of POD24 in relapsed/refractory follicular lymphoma-A SCHOLAR-5 analysis.
Journal: EJHaem
Published: January 08, 2025
Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma.
Journal: The Journal of clinical investigation
Published: December 17, 2024
Matching-Adjusted Indirect Comparisons of Axicabtagene Ciloleucel to Mosunetuzumab for the Treatment of Relapsed/Refractory Follicular Lymphoma.
Journal: Transplantation and cellular therapy
Published: February 21, 2024
A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: November 20, 2023
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
Journal: Expert review of anticancer therapy
Published: February 01, 2023
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
Journal: Cancer cell
Published: December 18, 2021
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity.
Journal: Blood cancer discovery
Published: December 03, 2021
Last Updated: 09/26/2026